The proceeds from the round will be used to develop and commercialize Obexelimab, the company’s leading drug candidate used in the treatment of IgG4-related disease, according to a Nov. 7 Zenas news release provided to Becker’s.
The company plans to launch a phase 3 registration trial for Obexelimab in late 2022 and launch the company’s other autoimmune disease programs in 2023, the release said.
Enavate Sciences led the funding round.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.